Sangleaf Pharm failed to give FDA requested records for OTC drugs, including children's toothpaste, at risk of DEG/EG contamination.
What happened
FDA reviewed import records and saw multiple drug shipments that named Sangleaf Pharm., Co., Ltd. as the manufacturer. FDA sent an electronic request for records on December 14, 2022, sent a second request on January 11, 2023, tried to call the registered U.S. agent on January 26, 2023, and sent a follow-up written request on January 27, 2023. Delivery was confirmed, but the company did not respond or provide the records.
What FDA found
The company did not respond to FDA's requests for records about the drugs it registered as manufacturing.
section 704(a)(4) of the FD&C Act (21 U.S.C. 374(a)(4))Refusing to permit access to or copying of records required by FDA is a prohibited act.
section 301(e) of the FD&C Act (21 U.S.C. 331(e))
What FDA wants
Respond in writing within 15 working days, identify the reply with FEI #3012845410 and ATTN Matthew R. Dionne, Pharm.D, Compliance Officer. The company may provide information for FDA to consider and/or request an FDA inspection.
Who should pay attention
- U.S. importers and distributors of Sangleaf drug products
- companies that buy OTC drugs or children's toothpaste from this contract manufacturer
- brands using foreign manufacturers with high-risk DEG/EG ingredients
This is a summary. Read the original letter on fda.gov.